Literature DB >> 16913723

Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones.

Nick P R Nieland1, Humphrey A Moynihan, Simon Carrington, Jillian Broadbear, James H Woods, John R Traynor, Stephen M Husbands, John W Lewis.   

Abstract

In recent years there has been substantial interest in the 14-aminodihydromorphinone derivatives methoclocinnamox (MC-CAM) and clocinnamox (C-CAM). To investigate the importance of the cinnamoyl ring substituent, a series of analogues have been prepared with chloro, methyl, and nitro substituents in the 2' and 4' positions. Despite some discrepancies between the in vitro and in vivo data, a clear SAR could be observed where the 2'-chloro and 2'-methyl ligands consistently displayed higher efficacy than their 4'-substituted analogues. The new series also followed the well-established SAR that 17-methyl ligands have greater efficacy at the mu opioid receptor than their 17-cyclopropylmethyl counterparts.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16913723      PMCID: PMC2443285          DOI: 10.1021/jm0604777

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  25 in total

1.  Structural determinants of efficacy for kappa opioid receptors in the orvinol series: 7,7-spiro analogues of buprenorphine.

Authors:  S M Husbands; J W Lewis
Journal:  J Med Chem       Date:  2000-01-27       Impact factor: 7.446

2.  A classification of opiate receptors that mediate antinociception in animals.

Authors:  M B Tyers
Journal:  Br J Pharmacol       Date:  1980-07       Impact factor: 8.739

3.  Bimorphinans as highly selective, potent kappa opioid receptor antagonists.

Authors:  A S Portoghese; A W Lipkowski; A E Takemori
Journal:  J Med Chem       Date:  1987-02       Impact factor: 7.446

4.  Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist.

Authors:  P S Portoghese; M Sultana; A E Takemori
Journal:  Eur J Pharmacol       Date:  1988-01-27       Impact factor: 4.432

5.  A rapid, high-yield conversion of codeine to morphine.

Authors:  K C Rice
Journal:  J Med Chem       Date:  1977-01       Impact factor: 7.446

6.  Dependence studies of new compounds in the rhesus monkey, rat, and mouse (1983).

Authors:  M D Aceto; L S Harris; E L May
Journal:  NIDA Res Monogr       Date:  1984-03

Review 7.  Opioid ligands having delayed long-term antagonist activity: potential pharmacotherapies for opioid abuse.

Authors:  Stephen M Husbands; John W Lewis
Journal:  Mini Rev Med Chem       Date:  2003-03       Impact factor: 3.862

8.  Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships.

Authors:  Elisabeth Greiner; Mariana Spetea; Roland Krassnig; Falko Schüllner; Mario Aceto; Louis S Harris; John R Traynor; James H Woods; Andrew Coop; Helmut Schmidhammer
Journal:  J Med Chem       Date:  2003-04-24       Impact factor: 7.446

9.  Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.

Authors:  J R Traynor; S R Nahorski
Journal:  Mol Pharmacol       Date:  1995-04       Impact factor: 4.436

10.  Common anionic receptor site hypothesis: its relevance to the antagonist action of naloxone.

Authors:  R J Kobylecki; R W Carling; J A Lord; C F Smith; A C Lane
Journal:  J Med Chem       Date:  1982-02       Impact factor: 7.446

View more
  13 in total

Review 1.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

2.  14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies.

Authors:  Guo Li; Lindsey C K Aschenbach; Hengjun He; Dana E Selley; Yan Zhang
Journal:  Bioorg Med Chem Lett       Date:  2008-12-29       Impact factor: 2.823

3.  Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity.

Authors:  Yunyun Yuan; Saheem A Zaidi; Orgil Elbegdorj; Lindsey C K Aschenbach; Guo Li; David L Stevens; Krista L Scoggins; William L Dewey; Dana E Selley; Yan Zhang
Journal:  J Med Chem       Date:  2013-11-07       Impact factor: 7.446

4.  14beta-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and related opioids. Further examples of pseudoirreversible mu opioid receptor antagonists.

Authors:  Nick P R Nieland; David Rennison; Jillian H Broadbear; Lauren Purington; James H Woods; John R Traynor; John W Lewis; Stephen M Husbands
Journal:  J Med Chem       Date:  2009-11-12       Impact factor: 7.446

Review 5.  Most recent developments and modifications of 14-alkylamino and 14-alkoxy-4,5-epoxymorphinan derivatives.

Authors:  L Stavitskaya; A Coop
Journal:  Mini Rev Med Chem       Date:  2011-10       Impact factor: 3.862

6.  Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties.

Authors:  Lauren C Purington; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

7.  Cinnamoyl derivatives of 7alpha-aminomethyl-6,14-endo-ethanotetrahydrothebaine and 7alpha-aminomethyl-6,14-endo-ethanotetrahydrooripavine and related opioid ligands.

Authors:  David Rennison; Adrian P Neal; Gerta Cami-Kobeci; Mario D Aceto; Fernando Martinez-Bermejo; John W Lewis; Stephen M Husbands
Journal:  J Med Chem       Date:  2007-09-22       Impact factor: 7.446

8.  Opioid receptor selectivity profile change via isosterism for 14-O-substituted naltrexone derivatives.

Authors:  Yan Zhang; Orgil Elbegdorj; Yunyun Yuan; Irina O Beletskaya; Dana E Selley
Journal:  Bioorg Med Chem Lett       Date:  2013-05-16       Impact factor: 2.823

9.  Mixed kappa/mu opioid receptor agonists: the 6 beta-naltrexamines.

Authors:  Gerta Cami-Kobeci; Adrian P Neal; Faye A Bradbury; Lauren C Purington; Mario D Aceto; Louis S Harris; John W Lewis; John R Traynor; Stephen M Husbands
Journal:  J Med Chem       Date:  2009-03-26       Impact factor: 7.446

10.  14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity.

Authors:  H Moynihan; A R Jales; B M Greedy; D Rennison; J H Broadbear; L Purington; J R Traynor; J H Woods; J W Lewis; S M Husbands
Journal:  J Med Chem       Date:  2009-03-26       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.